Our work demonstrating the clinical relevance of the epigenetic markers of an important biological candidate such as FABP3 can be a step towards clinical tests that measure epigenetic alterations that can predict patients’ risks of developing insulin, lipids and blood pressure phenotypes of MetS. This evidence concerns the gene INS and metabolic syndrome.